Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Khalil on Benefits Derived From the POSEIDON Regimen in Metastatic NSCLC

May 12th 2023

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Factors in Selecting IO Therapy for Patients With Advanced NSCLC

May 12th 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Considerations for Incorporating Perioperative Treatment in Resectable NSCLC

May 12th 2023

Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.

Dr Das on the Limited Landscape of Second-line Treatment Options in ES-SCLC

May 11th 2023

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

May 9th 2023

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

May 9th 2023

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Sintilimab Plus Chemo With or Without IBI305 Provides PFS Benefit in EGFR TKI–Pretreated EGFR+ NSCLC

May 8th 2023

The combination of sintilimab and chemotherapy with or without the bevacizumab biosimilar IBI305 produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after treatment with an EGFR TKI.

Dr Das on Updated Data Supporting the Use of Chemoimmunotherapy Regimens in ES-SCLC

May 5th 2023

Devika Das, MD, MSHQS,discusses updated data on the use of immunotherapy and platinum-based chemotherapy regimens in extensive-stage small cell lung cancer.

Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer

May 5th 2023

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?

May 5th 2023

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

Aumolertinib Plus SRT Elicits Responses in Intracranial Oligometastatic EGFR+ NSCLC

May 4th 2023

Administration of aumolertinib until intracranial oligoprogression, followed by salvage stereotactic radiation therapy, produced central nervous system responses with acceptable tolerability in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.

FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

May 4th 2023

The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Neoadjuvant Atezolizumab Followed by Adjuvant Atezolizumab May Benefit Select Patients With Early-stage NSCLC

May 3rd 2023

Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.

Updates in Gender-Based Treatment for Patients with Advanced NSCLC

May 2nd 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.

Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC

May 2nd 2023

Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.

First-line Cemiplimab Plus Chemo Wins Approval in Canada for Advanced NSCLC

May 2nd 2023

Health Canada has approved the combination of cemiplimab and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer without EGFR, ALK, or ROS1 aberrations who are not candidates for definitive chemoradiation.

Dr Skoulidis on Determinants of KRAS G12C Inhibitor Efficacy in NSCLC

May 1st 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses molecular determinants of KRAS G12C inhibitor efficacy in advanced non–small cell lung cancer.

Dr Lisberg on Emerging Post-Osimertinib Treatment Options in EGFR-mutant NSCLC

May 1st 2023

Aaron Lisberg, MD, discusses ongoing and future efforts to expand effective treatment options for patients with osimertinib-resistant, EGFR-mutant non–small cell lung cancer.

Dr Murciano-Goroff on the Investigation of KRAS G12C Inhibitor LY3537982 in Solid Tumors

April 28th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the investigation of the novel KRAS G12C inhibitor LY3537982 in patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Resectable Non–Small Cell Lung Cancer: Neoadjuvant Treatment Strategies

April 28th 2023

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.